Clinical Trial Update: Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Berodual Respimat with the Berodual MA Inhaler in patients with asthma, chronic obstructive pulmonary disease, or mixed conditions has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Berodual MA Inhaler (ipratropium bromide and fenoterol hydrobromide)
• Berodual Respimat (ipratropium bromide and fenoterol hydrobromide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive, Asthma | Phase 3 | Status: COMPLETED